45 Cours Gouffé
(a) HEMOSYSTEM is a biotechnology company devoted to the transfusion medicine. It's projects address the major transfusion issues : security and efficacy of blood products.
(b) Transfusion safety, Hemosystem has developed a rare event detector technology, ScanSystem(tm) for the detection of bacteria in blood products on a routine basis for screening blood donor components prior to transfusion. The method uses together a specific disposable to prepare the sample and a simple and rapid scanning device for solid phase cytometry able to detect a low number of fluorescent cells. HemoSystem develops also a simple and low cost method for the detection of leucocytes in blood products.
(c) Transfusion efficacy, Hemosystem is developing an additive solution to be added in blood components, able to extend their in vitro life span by 50%. This additive will be used to increase storage time for both platelets and red blood cells and to protect red blood cells during gamma irradiation, also improving their quality.
This additive is a naturally occurring substance that transports long chain fatty acids across cell membranes, improving cell membrane stability and preventing membrane ageing.
Product Names / Compound Descriptions:
ScanSystem™ (analyzer technology) and Lifesol™ (blood storage additive).
Hemosystem's vocation is to improve safety in the blood transfusion field, offering their range of products designed for this purpose to the different international blood transfusion systems.
Key Management Names and Titles:
Jean-Pierre HERMET - President & Chief Executive Officer email@example.com
Géraldine FRANKIDJIAN - Chief Financial Officer firstname.lastname@example.org
Isabelle BESSON-FAURE - Hematology Project Director email@example.com
Anne MONNOT DES ANGLES - Microbiology Project Director amonnot@hemosystem
Last Updated: 2-28-02
10 (15 by the end of the year)